Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20312287 | 0.73 | LOXL2 (0.37) | LOXL2 | |
| SCHEMBL333263 | 0.72 | PCSK9 (0.43) | CYP3A4ALDH1A1CYP1A2LMNAMEN1 | |
| SCHEMBL297677 | 0.72 | CHRNB2 (0.44) | CYP2D6CYP3A4ALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL29408427 | 0.72 | CHRNB2 (0.44) | CYP2D6CYP3A4ALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL11247295 | 0.70 | CA2 (0.48) | ALDH1A1CYP1A2LMNAMAPTMEN1 | |
| SCHEMBL11907695 | 0.69 | — | — | |
| SCHEMBL14983467 | 0.69 | KMT2A (0.35) | CYP2D6CYP3A4ALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL7078619 | 0.69 | SMN1; SMN2 (0.36) | CYP2D6CYP3A4ALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL20312299 | 0.68 | CYP19A1 (0.31) | — | |
| SCHEMBL14421513 | 0.67 | LMNA (0.47) | CYP2D6CYP3A4ALDH1A1CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10504732-B2 | Impurity diffusion agent composition and method for manufacturing semiconductor substrate | TOKYO OHKA KOGYO CO, LTD. (JP) | 2019-12-10 | — | — | US | disclosed |
| US-20180182624-A1 | IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180182624-A1 | IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-06-28 | — | — | US | disclosed |
| US-8647827-B2 | Fluorescent substrates for neurotransmitter transporters | VANDERBILT UNIVERSITY (US) | 2014-02-11 | — | — | US | disclosed |
| US-8647827-B2 | Fluorescent substrates for neurotransmitter transporters | VANDERBILT UNIVERSITY (US) | 2014-02-11 | — | — | US | disclosed |
| US-8314126-B2 | Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-11-20 | — | — | US | disclosed |
| US-20110229910-A1 | Fluorescent Substrates for Neurotransmitter Transporters | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110229910-A1 | Fluorescent Substrates for Neurotransmitter Transporters | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110229910-A1 | Fluorescent Substrates for Neurotransmitter Transporters | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-7947255-B2 | Exposing cell or extract to 4-(4-(dimethylamino)phenyl)-1-methylpyridinium iodide; high speed screening; kits | VANDERBILT UNIVERSITY (US) | 2011-05-24 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
| US-6060487-A | Indanol compounds | ADIR ET COMPAGNIE (FR) | 2000-05-09 | — | — | US | disclosed |
| US-5958927-A | PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ADIR ET COMPAGNIE (FR) | 1999-09-28 | — | — | US | disclosed |
| EP-0912548-A1 | PYRIDYLPYRROLE COMPOUNDS USEFUL AS INTERLEUKIN- AND TNF ANTAGONISTS | PFIZER INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0906912-A1 | Indanol derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-04-07 | — | — | EP | disclosed |
| WO-1998002430-A1 | PYRIDYLPYRROLE COMPOUNDS USEFUL AS INTERLEUKIN- AND TNF ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1998-01-22 | — | — | WO | disclosed |
| US-5502065-A | TREATING HEADACHES | PFIZER INC. (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0636129-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | Pfizer Limited (GB) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021178-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | PFIZER LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180182624-A1 | IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE | SLC43A1, SAMHD1, SNRPD2 | CYP2D6 1872/4885CYP3A4 2433/4885ALDH1A1 2704/4885 |
| US-10504732-B2 | Impurity diffusion agent composition and method for manufacturing semiconductor substrate | SLC43A1, SAMHD1, SNRPD2 | CYP2D6 1872/4885CYP3A4 2433/4885ALDH1A1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.